68 results found.

Diffuse Intrinsic Pontine Glioma Clinical Trial using Bevacizumab; Erlotinib; Temozolomide; Irradiation

Dana-Farber Cancer Institute - Recruiting 3 years to 18 years.
- Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas.
Bevacizumab; Erlotinib; Temozolomide; Irradiation

Glioma Clinical Trial using temozolomide (TMZ); bevacizumab [Avastin]; Radiotherapy

Hoffmann-La Roche - Recruiting 6 Months to 18 years.
- A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma.
temozolomide (TMZ); bevacizumab [Avastin]; Radiotherapy

Childhood Mixed Glioma, Untreated Childhood Anaplastic Astrocytom Clinical Trial using veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

Glioma, or Metastatic Brain Cancer Clinical Trial using ExAblate Transcranial System

InSightec - Recruiting 18 years to 75 years.
- A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors.
ExAblate Transcranial System

Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood A Clinical Trial using WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 37 Months to 21 years.
- A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

Glioblastoma, Glioma Clinical Trial using GDC-0084

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
GDC-0084

Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendrogliom Clinical Trial using Toca 511; 5-FC

Tocagen Inc. - Recruiting 18 years or older.
- A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma.
Toca 511; 5-FC

Malignant Glioma Clinical Trial using 18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Dr. Negrin University Hospital - Recruiting 18 years to 75 years.
- Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Malignant Gliomas Clinical Trial using CT-011

Hadassah Medical Organization - Recruiting 3 years to 90 years.
- A Phase I/ II Clinical Trial of CT-011 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme.
CT-011

Cholangiocarcinoma, Chondrosarcoma, Glioma, or Advanced Solid Tum Clinical Trial using AG-120

Agios Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation.
AG-120

Glioma Clinical Trial using Bevacizumab; PRDR

University of Wisconsin, Madison - Recruiting 18 years or older.
- .
Bevacizumab; PRDR

Nausea, Vomiting, or Glioma Clinical Trial using Aprepitant; Ondansetron

Duke University - Recruiting 18 years or older.
- A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen.
Aprepitant; Ondansetron

Glioma Clinical Trial using iMRI; conventional neuronavigation

Huashan Hospital - Recruiting 18 years to 70 years.
- 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial.
iMRI; conventional neuronavigation

Malignant Glioma, Glioblastoma, or Brain Cancer Clinical Trial using Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.
Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

Astrocytoma, Central Nervous System Tumor, Glioblastoma, Glioma, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Evaluation of the Natural History of Patients With Tumors of the Central Nervous System.

Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1.

Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, or High Clinical Trial using Lenalidomide; Radiation Therapy

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 21 years.
- A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas.
Lenalidomide; Radiation Therapy

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors.
DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Glioma, Glioblastoma, or Brain Tumor, Recurrent Clinical Trial using ANG1005; Bevacizumab

Angiochem Inc - Recruiting 18 years or older.
- A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma.
ANG1005; Bevacizumab

Diffuse Intrinsic Pontine Glioma, or High-grade Glioma Clinical Trial using Chemotherapy

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Chemotherapy

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using Montanide ISA-51/survivin peptide vaccine; sargramostim; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas.
Montanide ISA-51/survivin peptide vaccine; sargramostim; laboratory biomarker analysis

Pontine Glioma Clinical Trial using Vismodegib

Spectrum Health Hospitals - Recruiting 3 years to 18 years.
- A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma..
Vismodegib

Advanced Malignant Glioma, Anaplastic Astrocytomas, or Glioblasto Clinical Trial using AMG 595

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
AMG 595

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Clinical Trial using 3-Tesla magnetic resonance imaging; CEST-MRI; DW-MRI; DCE-MRI; DSC-MRI; IV administration of gadolinium-containing contrast agent

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers.
3-Tesla magnetic resonance imaging; CEST-MRI; DW-MRI; DCE-MRI; DSC-MRI; IV administration of gadolinium-containing contrast agent

Glioblastoma Multiforme, or Gliosarcoma Clinical Trial using AMG 102 with Avastin

Duke University - Recruiting 18 years or older.
- Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.
AMG 102 with Avastin

Recurrent Glioma Clinical Trial using Bevacizumab; Minocycline; Radiation

University of Utah - Recruiting 18 years or older.
- A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in Patients With Recurrent gliOma (RAMBO).
Bevacizumab; Minocycline; Radiation

Acoustic Schwannoma, Adult Anaplastic Astrocytoma, Adult Anaplast Clinical Trial using fluorine F 18 fluorodopa; positron emission tomography; computed tomography; diffusion-weighted magnetic resonance imaging; perfusion-weighted magnetic resonance imaging; therapeutic conventional surgery; biopsy; laboratory biomarker analysis

Mayo Clinic - Recruiting 7 years or older.
- Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas.
fluorine F 18 fluorodopa; positron emission tomography; computed tomography; diffusion-weighted magnetic resonance imaging; perfusion-weighted magnetic resonance imaging; therapeutic conventional surgery; biopsy; laboratory biomarker analysis

Brain and Central Nervous System Tumors Clinical Trial using polymorphism analysis; laboratory biomarker analysis; medical chart review

University of California, San Francisco - Recruiting 18 years or older.
- San Francisco Bay Area Adult Glioma Prognosis Study Protocol.
polymorphism analysis; laboratory biomarker analysis; medical chart review

Brain and Central Nervous System Tumors Clinical Trial using mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

High Grade Glioma Clinical Trial

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas.

Brain Tumor Clinical Trial using everolimus; immunohistochemistry staining method; laboratory biomarker analysis

University of California, San Francisco - Recruiting 18 years or older.
- Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma.
everolimus; immunohistochemistry staining method; laboratory biomarker analysis

CNS Tumor, Adult Clinical Trial using temozolomide

University of California, San Francisco - Recruiting 18 years or older.
- A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma.
temozolomide

Low-grade Glioma, Astrocytoma, Oligodendroglioma, or Mixed Oligoa Clinical Trial using RAD001

University of California, San Francisco - Recruiting 18 years or older.
- Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma.
RAD001

Glioma Clinical Trial using 5-Aminolevulinic acid (ALA); Placebo - ascorbic acid

St. Joseph's Hospital and Medical Center, Phoenix - Recruiting 18 years or older.
- Barrow 5-ALA Intraoperative Confocal Evaluation Trial.
5-Aminolevulinic acid (ALA); Placebo - ascorbic acid

Glioblastoma, Malignant Glioma, Brain Tumors, or Anaplastic Astro Clinical Trial using Stem Cell Radiotherapy (ScRT) and Temozolomide

Beth Israel Medical Center - Recruiting 18 years to 70 years.
- STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Stem Cell Radiotherapy (ScRT) and Temozolomide

Brain Neoplasm, or Glioma Clinical Trial using IL13-PE38QQR

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 17 years.
- An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma.
IL13-PE38QQR

Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood A Clinical Trial using oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years.
- A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Malignant Glioma, or Glioblastoma Clinical Trial using External beam radiotherapy

Rigshospitalet, Denmark - Recruiting 18 years or older.
- Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study.
External beam radiotherapy

Glioma, or Cerebral Metastases Clinical Trial using PET 18FDOPA

Centre Antoine Lacassagne - Recruiting 18 years to 85 years.
- Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET) in a Multidisciplinary Meeting Therapeutic Proposal When Caring for Patients Diagnosed Primary or Secondary Cerebral Tumors.
PET 18FDOPA

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

High Grade Glioma Clinical Trial using FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Brigham and Women's Hospital - Recruiting 18 years to 85 years.
- Personalized Translational Platform for Biomarker Discovery in Brain Tumors.
FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

HIGH GRADE GLIOMA Clinical Trial using TH-302; Placebo

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- A Phase 2, Investigator Initiated Study to Determine the Safety, Efficacy and CNS Penetration of TH-302 in Recurrent High Grade Astrocytoma Following Bevacizumab.
TH-302; Placebo

Optic Glioma, Pilocytic Astrocytoma, Low Grade Glioma, or Fibriul Clinical Trial using AZD6244

National Institutes of Health Clinical Center (CC) - Recruiting 3 years to 21 years.
- Phase 1 and Phase II Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma.
AZD6244

Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Clinical Trial using vorinostat; bevacizumab; temozolomide

National Cancer Institute (NCI) - Recruiting 3 years to 21 years.
- A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas.
vorinostat; bevacizumab; temozolomide

Astrocytoma, Oligoastrocytoma, Mixed, Ganglioneuroma, Glioma, Gan Clinical Trial using Irinotecan; Bevacizumab; FDOPA-PET/MRI imaging

Washington University School of Medicine - Recruiting N/A to 21 years.
- Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study.
Irinotecan; Bevacizumab; FDOPA-PET/MRI imaging

Glioma Clinical Trial using RAD001 (Everolimus)

University of Alabama at Birmingham - Recruiting 1 year to 21 years.
- A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas.
RAD001 (Everolimus)

Malignant Glioma, or Recurrent Ependymoma Clinical Trial using AdV-tk; valacyclovir; Radiation

Advantagene, Inc. - Recruiting 3 years to 21 years.
- A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors.
AdV-tk; valacyclovir; Radiation

Malignant Glioma (WHO Grade III or IV) Clinical Trial using CTO and Bevacizumab; CTO alone

Duke University - Recruiting 18 years or older.
- A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure.
CTO and Bevacizumab; CTO alone

Diffuse Intrinsic Pontine Glioma (DIPG) Clinical Trial using Melphalan hydrochloride

Sidney Kimmel Comprehensive Cancer Center - Recruiting 1 Month to 17 years.
- Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG)..
Melphalan hydrochloride

Medulloblastoma,, Rhabdomyosarcoma,, Neuroblastoma,, Hepatoblasto Clinical Trial using LDE225

Novartis - Recruiting 12 Months to 18 years.
- A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma.
LDE225

Glioma Clinical Trial using 68Ga-BNOTA-PRGD2

Peking Union Medical College Hospital - Recruiting 18 years or older.
- Diagnostic Performance and Evaluation Efficacy of Brain 68Ga-BNOTA-PRGD2 PET/CT in Pre-surgery Glioma Patients.
68Ga-BNOTA-PRGD2

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.
vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 13 years or older.
- Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, or Hi Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 1 year to 30 years.
- A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyo Clinical Trial using Metronomic Cyclophosphamide; Thalidomide

Washington University School of Medicine - Recruiting 5 years to 21 years.
- Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors.
Metronomic Cyclophosphamide; Thalidomide

Glioma, or Other Solid Tumours Clinical Trial using 2-hydroxyoleic acid (2-OHOA/2OHOA)

Lipopharma Therapeutics SL - Recruiting 18 years or older.
- A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minervalr) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma.
2-hydroxyoleic acid (2-OHOA/2OHOA)

Newly Diagnosed High-Grade Glioma Clinical Trial using Mebendazole

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Study of Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide.
Mebendazole

Malignancy, Glioma, or Radiotherapy Clinical Trial using Photon treatment plans; Proton Treatment Plans; Neurocognitive evaluation; Advanced MRI imaging

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- Detection of Vascular and Neuronal Changes Following Proton and/or Photon Radiotherapy in Patients Receiving Skull Base and/or Brain Radiation.
Photon treatment plans; Proton Treatment Plans; Neurocognitive evaluation; Advanced MRI imaging

Astrocytoma, Oligodendroglioma, or Oligodendroastrocytoma Clinical Trial using Radiotherapy; Temozolomide

Sun Yat-sen University - Recruiting 18 years to 60 years.
- Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma.
Radiotherapy; Temozolomide

Brain Neoplasms, Primary Malignant Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 18 years or older.
- Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers.

Malignant Glioma Clinical Trial

AHS Cancer Control Alberta - Recruiting 18 years or older.
- Comparative 2-D Tumor Analysis in Familial Gliomas.

Glioma Clinical Trial

University of Lausanne Hospitals - Recruiting 18 years or older.
- Impact of Multimodal Diagnostic Assessment of Cerebral Gliomas With F-18-fluoroethyl-L-tyrosine PET/CT, F-18-fluorocholine PET/CT and Magnetic Resonance Imaging and Spectroscopy.

High-grade Glioma of the Brain Clinical Trial using PET images with 18F-fluoromethylcholine

University Ghent - Recruiting 18 years or older.
- PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?.
PET images with 18F-fluoromethylcholine

Diffuse Intrinsic Brainstem Gliomas Clinical Trial using Radiotherapy; Nimotuzumab

Eurofarma Laboratorios S.A. - Recruiting 3 years to 18 years.
- Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma.
Radiotherapy; Nimotuzumab

Brain and Central Nervous System Tumors Clinical Trial using temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial..
temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

Glioma Clinical Trial using GM-K562 Vaccination

Massachusetts General Hospital - Recruiting 18 years or older.
- A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor.
GM-K562 Vaccination

Glioma Clinical Trial using Temozolomide and Bevacizumab

Kentuckiana Cancer Institute - Recruiting 18 years to 75 years.
- A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma.
Temozolomide and Bevacizumab

Epilepsy, or Glioma Clinical Trial

VU University Medical Center - Recruiting 18 years or older.
- Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy.